Watch INTI. Know when insiders buy.
One email the day a filing lands. Free.
INTI
Inhibitor Therapeutics, Inc.
0.09
+0.00 +0.00%
USD · close Sep 17
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
50
WATCH · shorts 50
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $15.5MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$3.3MNET CASH $494K52W 0.04 – 0.12SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$619K | −$614K | — | 0.00 | −$775K | — | — | Aug 14 |
| Q1 2026 · Mar 31 | — | — | — | −$696K | −$686K | — | 0.00 | −$1.1M | — | — | Aug 14 |
| Q4 2025 · Dec 31derived | — | — | — | −$1.3M | −$1.3M | — | -0.01 | −$601K | — | — | Mar 26 |
| Q3 2025 · Sep 30 | — | — | — | −$741K | −$712K | — | 0.00 | −$761K | — | — | Nov 13 |
| Q2 2025 · Jun 30 | — | — | — | −$696K | −$660K | — | 0.00 | −$584K | — | — | Aug 14 |
| Q1 2025 · Mar 31 | — | — | — | −$675K | −$633K | — | 0.00 | −$1.3M | — | — | Aug 14 |
| Q4 2024 · Dec 31derived | — | — | — | −$1.5M | −$1.4M | — | -0.01 | −$771K | — | — | Mar 26 |
| Q3 2024 · Sep 30 | — | — | — | −$813K | −$731K | — | 0.00 | −$720K | — | — | Nov 13 |
| Q2 2024 · Jun 30 | — | — | — | −$585K | −$502K | — | 0.00 | −$583K | — | — | Nov 13 |
| Q1 2024 · Mar 31 | — | — | — | −$775K | −$685K | — | 0.00 | −$1.2M | — | — | Nov 13 |
| Q4 2023 · Dec 31derived | — | — | — | −$1.3M | −$1.2M | — | -0.01 | −$698K | — | — | Mar 28 |
| Q3 2023 · Sep 30 | — | — | — | −$760K | −$665K | — | 0.00 | −$563K | — | — | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$3.4M | −$3.3M | — | -0.02 | −$3.2M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$3.7M | −$3.3M | — | -0.02 | −$3.2M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$3.4M | −$3M | — | -0.02 | −$2.7M | — | — | — | — |
| FY2022 · to Dec 31 | — | — | −$658K | $12.1M | — | 0.03 | $11.7M | — | — | — | — |
| FY2021 · to Dec 31 | $0 | — | −$325K | −$299K | — | 0.00 | −$220K | — | — | — | — |
| FY2020 · to Dec 31 | $0 | — | −$1.1M | −$1.1M | — | 0.00 | −$825K | — | — | — | $0 |
Every number comes from Inhibitor Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.